Telix Pharmaceuticals Limited Stock Nasdaq
Stocks
TLX
US87961M1053
Biotechnology & Medical Research
OTC Markets Traded|
Market Closed -
Nasdaq
23:00:00 04/09/2026 +03
|
5-day change | 1st Jan Change | ||
| 11.94 USD | +1.70% |
|
+5.76% | +59.41% |
| 09-03 | ASX Biggest Gainers | MT |
| 09-02 | Telix Pharmaceuticals Completes Patient Enrollment for Phase 3 Study of Imaging Agents in Prostate Cancer | MT |
| Market Cap | 5.6B 4.03B 3.47B 3.27B 2.98B 5.58B 381B 38.59B 14.98B 195B 15.15B 14.82B 630B | P/E 2026 * |
251x | P/E 2027 * | 211x |
|---|---|---|---|---|---|
| Enterprise Value | 6.03B 4.34B 3.74B 3.52B 3.21B 6.01B 410B 41.55B 16.12B 210B 16.31B 15.95B 678B | EV / Sales 2026 * |
4.4x | EV / Sales 2027 * | 3.86x |
| Free-Float |
83.1% | Yield 2026 * |
-
| Yield 2027 * | - |
| Markets | Quality | ||
|---|---|---|---|
Nasdaq
| TLX | Delayed | |
CBOE
| TLX | Real-time | |
|
Deutsche Boerse AG
| Delayed | ||
|
Deutsche Boerse AG
| T3X0 | End-of-day quote |
Last Transcript : Telix Pharmaceuticals Limited
| 1 day | +1.70% | ||
| 1 week | +5.76% | ||
| Current month | +7.66% | ||
| 1 month | +16.03% | ||
| 3 months | +25.16% | ||
| 6 months | +73.80% | ||
| Current year | +59.41% |
| 1 week | 10.8 |  | 11.95 |
| 1 month | 10.44 | | 12.48 |
| Current year | 6.28 | | 12.48 |
| 1 year | 6.28 | | 12.48 |
| 3 years | 6.28 | | 30.36 |
| 5 years | 6.28 | | 30.36 |
| 10 years | 6.28 | | 30.36 |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 51 | 03/01/2017 | |
Darren Smith
DFI | Director of Finance/CFO | 61 | 31/07/2022 |
| Chief Tech/Sci/R&D Officer | - | - |
| Director | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 51 | 03/01/2017 | |
Mark Nelson
CHM | Chairman | 66 | 03/02/2026 |
Jann Skinner
BRD | Director/Board Member | 68 | 19/06/2018 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +1.70% | +5.76% | - | - | 4.03B | |
| -2.54% | -2.84% | -1.90% | +14.52% | 48.93B | |
| -0.40% | +1.03% | +439.20% | +499.20% | 45.01B | |
| -1.42% | +2.30% | +45.46% | +19.36% | 44.07B | |
| -1.22% | -2.31% | +12.40% | +71.48% | 40.73B | |
| +0.53% | -1.36% | +16.04% | +48.23% | 33.52B | |
| -0.21% | +9.14% | - | - | 17.77B | |
| -0.35% | -1.56% | +22.59% | +116.19% | 16.5B | |
| -1.01% | +0.50% | +15.83% | +27.98% | 14.67B | |
| -1.65% | -1.03% | +77.75% | +37.63% | 13.77B | |
| Average | -0.66% | +0.53% | +78.42% | +104.33% | 30.55B | |
| Weighted average by Cap. | -0.99% | +0.11% | +94.86% | +122.11% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 1.37B 986M 849M 798M 729M 1.36B 93.1B 9.43B 3.66B 47.77B 3.7B 3.62B 154B | 1.58B 1.14B 978M 920M 841M 1.57B 107B 10.88B 4.22B 55.07B 4.27B 4.18B 177B |
| Net income | 24.99M 18.02M 15.5M 14.59M 13.32M 24.93M 1.7B 172M 66.88M 873M 67.65M 66.18M 2.81B | 13.8M 9.94M 8.56M 8.05M 7.35M 13.76M 939M 95.14M 36.92M 482M 37.34M 36.53M 1.55B |
| Net Debt | 429M 309M 266M 250M 229M 428M 29.2B 2.96B 1.15B 14.98B 1.16B 1.14B 48.26B | 497M 358M 308M 290M 265M 495M 33.8B 3.42B 1.33B 17.34B 1.34B 1.31B 55.87B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 04/09/26 | $11.94 | +1.70% | 142,006 |
| 03/09/26 | $11.74 | +2.53% | 139,774 |
| 02/09/26 | $11.45 | +5.53% | 239,368 |
| 01/09/26 | $10.85 | -2.16% | 186,285 |
| 31/08/26 | $11.09 | -1.77% | 121,913 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- TLX Stock
- TLX Stock
Select your edition
All financial news and data tailored to specific country editions
